Aura Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in three upcoming investor conferences in May 2025:

• The Citizens Life Sciences Conference - Fireside Chat on May 8, 2025, at 9:30 a.m. ET
• H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - Fireside Chat on May 20, 2025, at 2:00 p.m. ET
• TD Cowen 6th Annual Oncology Innovation Summit - Fireside Chat on May 27, 2025, at 10:00 a.m. ET

Live webcasts will be available on the company's investor relations website, with replays accessible for 90 days after each presentation.

News Market Reaction – AURA

+1.32%

1 alert

+1.32% News Effect

On the day this news was published, AURA gained 1.32%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:

• The Citizens Life Sciences Conference on Thursday, May 8, 2025.
  Fireside Chat at 9:30 a.m. ET.

• H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025.
  Fireside Chat at 2:00 p.m. ET.

• TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025.
  Fireside Chat at 10:00 a.m. ET.
  
  

The live webcasts of the fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of each webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Investor and Media Contact:

Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com

FAQ

What investor conferences will Aura Biosciences (AURA) attend in May 2025?

Aura Biosciences will participate in three conferences: The Citizens Life Sciences Conference (May 8), H.C. Wainwright BioConnect Investor Conference (May 20), and TD Cowen Oncology Innovation Summit (May 27).

When is Aura Biosciences' presentation at the H.C. Wainwright BioConnect Conference?

Aura Biosciences will present a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20, 2025, at 2:00 p.m. ET.

How can I access Aura Biosciences' (AURA) investor conference webcasts?

The webcasts can be accessed on Aura Biosciences' website at ir.aurabiosciences.com under the 'Events & Presentations' section, where replays will be available for 90 days after each presentation.

What type of company is Aura Biosciences (AURA)?

Aura Biosciences is a clinical-stage biotechnology company that develops precision therapies for solid tumors designed to preserve organ function.